Peptides
PE-22-28
Also called PE-22-28
PE-22-28 interests people looking for better mood, motivation and relief from the flat feeling of anhedonia. Its appeal is a different approach from familiar antidepressants. The published experimental work is in cells and mice, while user experiences include both meaningful improvement and little benefit or worsening symptoms.
Dosage & duration
One public self-report · not a common or validated regimen
One reported nonmedical example
Reported use · unapproved regimen- Dose
- 200 mcg per day
- How often
- Once each morning, subcutaneous
- How long
- Approximately 8 weeks on, 2 weeks off in follow-up
The author also describes it as 60 days before a break. These are that person’s approximate reports, not evidence of safe cycling or a recommendation.
Do not change an antidepressant or mood-stabilizer schedule based on this account. Clinical interaction and long-term safety data are lacking.
Why people consider PE-22-28
Enjoyment and motivation, with mixed experiences
What people hope for
-
Enjoy things again
Less emotional flatness and more interest in everyday life.
-
Get started
Less difficulty beginning and finishing daily tasks.
What reports also include
-
Little change
Some people describe little or no benefit.
-
Feeling worse
Other reports describe worsening symptoms rather than relief.
Why does it attract mood-focused users?
Readers often want motivation and enjoyment back, rather than a stimulant-like feeling. PE-22-28 emerged from research into a channel involved in nerve-cell activity. A new mechanism is interesting, but does not establish a faster or better antidepressant for people.
What do actual users report?
The inspected discussion includes easier task initiation and social enjoyment, alongside comments describing no benefit or worse symptoms. The author used other peptides too. These accounts help explain the questions readers ask; they cannot estimate a success rate or identify the cause of improvement.
Is there a dependable cycle?
The dose box keeps one person’s amount and timing together. Their approximate eight-week course is not a studied treatment duration. Mouse behavioral results cannot supply an equivalent human dose or prove that a break prevents tolerance.
What about combining it with an SSRI?
A different proposed mechanism is not evidence of a safe interaction. Bring the exact product to the clinician managing existing medication rather than stopping treatment or adding a peptide on that assumption. Worsening depression deserves prompt support, not an escalating experiment.
Model details: PE-22-28 · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 0.48 h is not measured human elimination. Original paper distinguishes PE22-28 from spadin and modified derivatives.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.48 hours
- Absorption half-life assumed
- 0.12 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- IC50 and behavioral effect persistence must not calibrate circulating concentration.
- No human route/dose concentration-time profile established in reviewed sources.
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, <i>In Vivo</i> Stability and Antidepressant Activity.
Legacy 0.48 h is not measured human elimination. Original paper distinguishes PE22-28 from spadin and modified derivatives.
pe-22-28-relative-timing-2026-10 · version 1
Common questions
Does PE-22-28 work within days?
Some users report early changes, but no human trial establishes a dependable onset. Mouse behavioral timing does not predict an individual response.
Is it safe with an SSRI?
The reviewed evidence does not establish combination safety. A different mechanism is not enough to answer that question or justify changing prescribed medication.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- Task initiation and enjoyment are common goals in the inspected discussion.
- Human response
- A positive account cannot establish how often it helps.
- Other medicines
- A different mechanism does not prove an antidepressant combination is safe.
- 1. Djillani et al.: shortened spadin analogues
Original full paper inspected: channel experiments and mouse behavioral work; no human antidepressant trial.
- 2. Shortened Spadin Analogs Display Better TREK-1 Inhibition, <i>In Vivo</i> Stability and Antidepressant Activity.
Legacy 0.48 h is not measured human elimination. Original paper distinguishes PE22-28 from spadin and modified derivatives.
- 3. Djillani et al. 2017 — shortened spadin analogues
PE-22-28 channel experiments, mouse behavioral tests and action-duration observations; no human antidepressant trial.
- 4. Mazella et al. 2010 — parent spadin
Original TREK-1/spadin research in cells and mice; parent distinguished from the shortened peptide.
Related compounds and examples
Related compounds
Semax
Semax for focus and mental fatigue: nasal-drop examples, concentration differences and realistic expectations for everyday nootropic use.
Selank
Selank for anxiety and calm focus: nasal-drop context, comparison with Semax and what to expect from the limited human research.
Adamax
Adamax versus Semax: focus and motivation claims, a named reported-dose example and the uncertainty behind “stronger” nootropic marketing.